Ceribell Secures FDA Breakthrough Device Designation for LVO Stroke Detection Monitor

Ceribell, Inc., a medical technology company specializing in neurological care, has received the U.S. Food and Drug Administration’s Breakthrough Device designation for its Large Vessel Occlusion (LVO) stroke detection monitor for hospitalized patients.

This innovative monitor combines Ceribell’s existing hardware with an AI-driven algorithm to analyze EEG signals, allowing for earlier identification of LVO strokes. 

The development builds on the company’s recent FDA 510(k) clearances for the Clarity® algorithm, which detects neonatal seizures, as well as its delirium screening solution.

LVO strokes are especially severe, carrying higher rates of morbidity and mortality than other ischemic strokes. Rapid detection and treatment are critical, as each minute saved can significantly reduce long-term disability. 

In-hospital strokes, which occur in up to 17% of stroke patients, are frequently identified later than community-onset strokes, often resulting in poorer outcomes.

The FDA designation acknowledges the monitor’s potential to deliver timely and accurate detection of LVO strokes, supported by multi-center validation studies. 

Ceribell plans to continue advancing its point-of-care EEG technology, with the goal of establishing brain monitoring as a standard vital sign in hospitals, ultimately improving care and outcomes for high-risk patients.